NVO
Novo Nordisk sues Eli Lilly over misleading weight loss drug ads
Article Summary
HOLD- Novo Nordisk (NYSE: NOVO) filed a lawsuit against Eli Lilly alleging that ad campaigns for Zepbound and Mounjaro mislead consumers by using outdated clinical data to suggest those treatments are more effective than Novo's rival injections, seeking permanent court order prohibiting ads and financial damages.
- Novo Nordisk ADR argues that ads comparing Lilly's drug to Novo's Wegovy and Ozempic omit more recent data from higher-dose versions of both products.
- The lawsuit comes as Novo works to recover ground it has lost to Lilly in the weight loss drug market, with WegovY recently surpassing 3 million prescriptions and strategic price cuts as part of its effort to claw back market share.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 16.8% | 25% | 60.0 ptsModerate (16.8%) - Decent growth |
| EPS Growth Next 5Y ? | -0.9% | 25% | 0.0 ptsNegative (-0.9%) - Declining expectations |
| Target Price Upside ? | 0.8% | 20% | 20.0 ptsMinimal Upside (0.8%) - Target: $49.81 vs Current: $49.43 |
| Gross Margin % ? | 81.8% | 15% | 100.0 ptsExceptional (81.8%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -31.2% | 15% | 80.0 ptsSolid Dip (-31.2%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About NVO
- Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
- It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
- The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
- The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
- The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management.
- It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa.
- Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.